Pharvaris Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Pharvaris Value Chain Analysis helps you understand how Pharvaris creates value across its support and primary activities in a clear, practical framework. This page already shows a real preview of the analysis, so you can review the style and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Pharvaris kept firm infrastructure lean in fiscal 2025, because a clinical-stage model lives or dies on cash control and tight governance. With a small HAE pipeline of 2 programs, capital allocation has to stay disciplined, and board-level oversight helps protect IP, trial spend, and milestone timing. One clean rule: every euro must back data, regulatory progress, or patent value.
Human Resource Management
Pharvaris' human resource management depends on a lean, highly specialized team in clinical development, regulatory affairs, CMC, and rare-disease science, because its 2025 work centers on one core therapeutic platform. That matters when a biotech must coordinate outsourced trials and manufacturing while keeping decision-making tight and fast. In 2025, the key HR job is to hire scarce experts, retain them, and align them around the same program milestones and cash discipline.
Technology Development
Pharvaris's technology development centers on bradykinin B2 receptor science and oral formulation work, led by deucrictibant for hereditary angioedema (HAE). Its pipeline targets both on-demand and prophylactic use, which matters because HAE affects about 1 in 50,000 people and oral dosing can reduce the burden of injections. By 2025, Pharvaris had advanced through clinical data generation in Phase 3 programs, a costly step for a biotech that reported no product revenue and relies on R&D spending to build its edge.
Procurement
Pharvaris uses CRO, CDMO, lab, and clinical-site partners instead of large internal plants, so procurement is a core cost gate in 2025. That keeps fixed asset needs light, but it makes vendor quality, delivery timing, and supply continuity central to trial execution. In a clinical-stage model, a single supplier miss can delay data readouts and raise cash burn.
Pharvaris Keeps It Lean, Cash-Focused, and Phase 3 Driven
In fiscal 2025, Pharvaris kept support activities lean: a small team, outsourced trials, and tight board control around a 2-program HAE pipeline. Procurement and vendor oversight mattered most, since the group had no product revenue and every spend had to support data, regulation, or IP. One rule drove the model: protect cash and hit Phase 3 milestones.
| 2025 cue | Value |
|---|---|
| Programs | 2 |
| Product revenue | 0 |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
In 2025, Pharvaris stayed pre-commercial, so inbound logistics was small and tightly controlled, not built for mass inventory. It brought in research materials, drug substance, excipients, reference standards, and clinical trial supplies for its hereditary angioedema (HAE) programs. The flow depended on external manufacturers and study sites, which kept stock low and quality control strict.
Operations
Pharvaris's operations center on target validation, oral formulation work, clinical trials, data analysis, and regulatory prep for hereditary angioedema. In fiscal 2025, it still had no product revenue, so value creation came from turning one bradykinin B2 receptor mechanism into testable oral therapies. Each trial readout reduces development risk and supports the next filing step.
Outbound Logistics
In 2025, Pharvaris's outbound logistics stayed trial-led: investigational product and study materials were shipped only to clinical centers, with documentation tightly tracked under GxP rules. There is still no broad commercial distribution network, so the flow is small, controlled, and tied to ongoing clinical site demand. That keeps shipping risk low, but each batch needs exact chain-of-custody and audit support.
Marketing and Sales
In FY2025, Pharvaris had no approved product, so marketing and sales were aimed at HAE medical education, rare-disease community outreach, investigator engagement, and investor messaging. This work is less about selling today and more about building trial awareness, speeding site enrollment, and preparing launch demand. For a pre-revenue biotech, that means each meeting with clinicians, patients, and investors helps reduce future launch friction.
Service
For Pharvaris, Service covers patient support in trials, safety follow-up, medical information, and readiness for future commercialization. In rare disease, trust and adherence drive value because patients are few, symptoms can be severe, and every post-dose check matters. This layer helps Pharvaris protect data quality now and build the support model it will need at launch.
Pharvaris: FY2025 stayed R&D-led, with no product revenue yet
In FY2025, Pharvaris's primary activities were R&D-led: oral HAE drug development, clinical trials, regulatory prep, and data analysis. With no approved product and no product revenue, value creation came from lowering clinical and filing risk, not from commercial scale.
| FY2025 | Data |
|---|---|
| Product revenue | 0 |
| Focus | R&D |
| Stage | Pre-commercial |
What You See Is What You Get
Pharvaris Reference Sources
This is the actual Pharvaris Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional version. The preview below is taken directly from the complete report, so what you see is exactly what you get. Unlock the full document after checkout for the complete analysis.
Frequently Asked Questions
Pharvaris creates value by turning 1 core bradykinin-B2 receptor strategy into 2 HAE treatment formats, on-demand and prophylactic. The model is still clinical-stage, so value depends on trial success, regulatory progress, and future commercialization rather than sales volume. That makes R&D, quality, and vendor execution the main economic levers.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.